329 results on '"Jung, Gundram"'
Search Results
2. CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
3. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
4. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
5. BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
6. Identification of CD105 (endoglin) as novel risk marker in CLL
7. Immunocytokines with target cell–restricted IL-15 activity for treatment of B cell malignancies
8. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer
9. Identification of CD318 (CDCP1) as novel prognostic marker in AML
10. 1353 An Fc-optimized B7-H3-targeting antibody for treatment of ovarian cancer
11. 1365 An immunocytokine with target cell-restricted IL-15 activity for induction of anti-tumor immunity against acute myeloid leukemia
12. Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity
13. ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL
14. An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
15. Cloned Transgenic Farm Animals Produce a Bispecific Antibody for T Cell-Mediated Tumor Cell Killing
16. Clinical development of the bispecific PSMAxCD3 antibody CC-1.
17. CD105 (Endoglin) as negative prognostic factor in AML
18. The challenges of translation
19. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
20. Figure S2 from The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia
21. Data from The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia
22. Supplementary Figure 1 from Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells
23. Supplementary Movie from Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells
24. Supplementary Figure 1 from RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia
25. Data from Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells
26. Supplementary Figure 2 from RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia
27. Data from RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia
28. Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
29. Bispecific Antibodies for the Treatment of Cancer: The Challenges of Translation
30. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
31. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
32. Monoclonal and Bispecific Antibodies as Novel Therapeutics
33. IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
34. Abstract 2859: Platelet-derived TGFβ undermines treatment efficacy of t cell recruiting bispecific antibodies
35. Abstract CT141: CC-1, a bispecific PSMAxCD3 antibody for treatment of prostate carcinoma: Results of the ongoing phase I dose escalation trial
36. Abstract 2078: CLN-049 is a bispecific T cell engaging IgG-like antibody targeting FLT3 on AML cells
37. Abstract 2860: A CD135 immunocytokine with target cell-restricted IL-15 activity for treatment of AML
38. Abstract 2865: CC-3, an IgG-based B7-H3xCD3 bispecific antibody for targeting of gastrointestinal cancers
39. Abstract 2886: Antigen internalization and its prevention during treatment with bispecific antibodies
40. Abstract 2864: A CLEC12A immunocytokine with target cell-restricted IL-15 activity shows a favorable toxicity profile and high potency in AML
41. Abstract 2863: Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies
42. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
43. Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
44. CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
45. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia
46. Activation of Human Peripheral Blood Mononuclear Cells by Anti-T3: Killing of Tumor Target Cells Coated with Anti-Target--Anti-T3 Conjugates
47. Lymphokine-Activated Killer Cells Targeted by Monoclonal Antibodies to the Disialogangliosides GD2 and GD3 Specifically Lyse Human Tumor Cells of Neuroectodermal Origin
48. Disialoganglioside GD3 on Human Melanoma Serves as a Relevant Target Antigen for Monoclonal Antibody-Mediated Tumor Cytolysis
49. The Cytolytic Protein of Human Lymphocytes Related to the Ninth Component (C9) of Human Complement: Isolation from Anti-CD3-Activated Peripheral Blood Mononuclear Cells
50. Induction of Synthesis of the Cytolytic C9 (Ninth Component of Complement)-Related Protein in Human Peripheral Mononuclear Cells by Monoclonal Antibody OKT3 or Interleukin 2: Correlation with Cytotoxicity and Lymphocyte Phenotype
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.